X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
2.830
0.00 (0.00%)
At close: Oct 2, 2026, 4:00 PM EDT
2.800
-0.030 (-1.06%)
After-hours: Oct 2, 2026, 7:30 PM EDT
X4 Pharmaceuticals Revenue
X4 Pharmaceuticals had revenue of $8.81M in the quarter ending June 30, 2026, with 346.33% growth. This brings the company's revenue in the last twelve months to $15.85M, down -51.65% year-over-year. In the year 2025, X4 Pharmaceuticals had annual revenue of $35.11M with 1,273.21% growth.
Revenue (ttm)
$15.85M
Revenue Growth
-51.65%
P/S Ratio
17.49
Revenue / Employee
$352,156
Employees
45
Market Cap
280.59M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.11M | 32.56M | 1,273.21% |
| Dec 31, 2024 | 2.56M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| Q32 Bio | 53.74M |
| Abeona Therapeutics | 25.52M |
| Fate Therapeutics | 6.49M |
| Upstream Bio | 3.16M |
| EyePoint | 2.79M |
XFOR News
- 1 day ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - X4 Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 23 days ago - X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference - GlobeNewsWire
- 24 days ago - X4 Pharmaceuticals announces results from Type C Meeting with FDA - TheFly
- 24 days ago - X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals treatment of congenital neutropenia gets orphan designation - TheFly
- 1 month ago - X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c) - TheFly